Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by parenchymal scarring, leading progressively to alveolar architecture distortion, respiratory failure, and eventually death. Currently, there is no effective treatment for IPF. Previously, 3′5-dimaleamylbenzoic acid (3′5-DMBA), a maleimide, demonstrated pro-apoptotic, anti-inflammatory, and anti-cancer properties; however, its potential therapeutic effects on IPF have not been addressed. Bleomycin (BLM) 100 U/kg was administered to CD1 mice through an osmotic minipump. After fourteen days of BLM administration, 3′5-DMBA (6 mg/kg or 10 mg/kg) and its vehicle carboxymethylcellulose (CMC) were administered intragastrically every two days until day 26. On day 28, all mice were euthanized. The 3′5-DMBA effect was assessed by histological and immunohistochemical staining, as well as by RT-qPCR. The redox status on lung tissue was evaluated by determining the glutathione content and the GSH/GSSG ratio. 3′5-DMBA treatment re-established typical lung histological features and decreased the expression of BLM-induced fibrotic markers: collagen, α-SMA, and TGF-β1. Furthermore, 3′5-DMBA significantly reduced the expression of genes involved in fibrogenesis. In addition, it decreased reduced glutathione and increased oxidized glutathione content without promoting oxidative damage to lipids, as evidenced by the decrease in the lipid peroxidation marker 4-HNE. Therefore, 3′5-DMBA may be a promising candidate for IPF treatment.
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease characterized by high mortality and marked clinical heterogeneity. A defining yet insufficiently understood feature of IPF is its frequent coexistence with pulmonary and extrapulmonary comorbidities. However, the molecular basis that underlies this multisystem involvement remains unclear. We applied an integrative systems-level framework that combines lung-derived transcriptomic datasets with curated disease–gene associations across major IPF-associated comorbidities. Network organization and functional stratification analyses were used to characterize shared and disease-specific molecular modules, and independent transcriptomic datasets were analyzed to evaluate the consistency of these patterns. These analyses revealed structured molecular convergence between IPF and its comorbidities organized into two interacting biological programs: a lung-enriched fibrotic–mechanical program and a systemically distributed neuroimmune–metabolic program. These programs are interconnected through a shared regulatory interface that includes IL6, AKT1, TGFB1 and STAT3. This organization was consistently observed across independent datasets. IPF emerges from the interaction between pulmonary and systemic regulatory programs rather than isolated lung-restricted mechanisms. This framework provides a basis for understanding disease heterogeneity and comorbidity burden, with potential implications for stratification and therapeutic targeting.